Headache News and Research

Latest Headache News and Research

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.

23 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

Study investigates links between GWI and veterans' locations during war

Gulf War Illness (GWI)-the chronic health condition that affects about one in four military veterans of the 1991 Gulf War-appears to be the result of several factors, which differed in importance depending upon the locations where veterans served during the war, according to a Baylor University study.

19 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Alexion Pharmaceuticals, Inc. today announced that the Company's study of eculizumab in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

15 Sep 2011

Jefferson neurologist receives Harold G. Wolff Lecture Award for migraine headache model

Michael L. Oshinsky, Ph.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and a member of the Jefferson Headache Center team, was recently named the 2011 Harold G. Wolff Lecture award recipient for creating a new animal model of migraine headache.

14 Sep 2011

Merck issues statement on GARDASIL human papillomavirus vaccine

Merck, known as MSD outside the United States and Canada, issued the following statement on GARDASIL, Merck's vaccine to protect against certain diseases caused by human papillomavirus (HPV) types 6, 11, 16 and 18.

14 Sep 2011

Viewpoints: Medicare bigger problem than social security; N.Y.'s long term care 'bad grade'

Sometimes they challenged Perry from the left (on Social Security and Medicare) and sometimes from the right (on immigration, taxes and mandatory vaccines), but it all came back to the same thing: The frontrunner was befuddled – seemingly stunned that his rivals would question his right to the Republican presidential nomination.

14 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

Mosquitoes carrying West Nile virus detected

There is a recent surge in the West Nile-carrying mosquitoes after a relatively dry spell accompanied by warm temperatures last week. The health department monitors about 40 traps across the county two times per week, and last week found four traps in Wheaton alone with infected mosquitoes.

12 Sep 2011

First-ever comprehensive study of species origins of nature-derived drugs

In a first-ever comprehensive study of the species origins of nature-derived drugs, it is shown that drug-producing species are concentrated and clustered in a limited number of families, refuting the conventional view that as every nature species produces biologically active molecules, one can find drugs from almost any major block of species groups if one looks for them hard enough.

8 Sep 2011

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received the industry's first and only regulatory approval for the use of an implanted neurostimulation device for patients with intractable chronic migraine.

7 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Many athletes hold unscientific views about benefits of different hydration practices

Nearly half of recreational runners may be drinking too much fluid during races, according to a survey of runners by Loyola University Health System researchers.

3 Sep 2011

AAN calls all high school coaches, athletes and parents to learn signs of sports concussion

The American Academy of Neurology, the leading group of neurologists dedicated to managing sports concussion, is issuing a call to all youth and high school coaches, athletes and parents to learn the signs of sports concussion and to know when a player must leave the game.

2 Sep 2011

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

A new meta-analysis published this week in Drugs in R&D, reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.

2 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

Headache News and Research

Latest Headache News and Research

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Study investigates links between GWI and veterans' locations during war

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Jefferson neurologist receives Harold G. Wolff Lecture Award for migraine headache model

Merck issues statement on GARDASIL human papillomavirus vaccine

Viewpoints: Medicare bigger problem than social security; N.Y.'s long term care 'bad grade'

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

Mosquitoes carrying West Nile virus detected

First-ever comprehensive study of species origins of nature-derived drugs

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Many athletes hold unscientific views about benefits of different hydration practices

AAN calls all high school coaches, athletes and parents to learn signs of sports concussion

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in